WuXi Biologics (Cayman) Inc. (HKG:2269)

Market Cap	209.29B +73.6%
Revenue (ttm)	24.25B +16.7%
Net Income	5.46B +46.3%
EPS	1.29 +47.9%
Shares Out	4.10B
PE Ratio	39.49
Forward PE	30.65
Dividend	n/a
Ex-Dividend Date	n/a

Volume	37,244,280
Open	49.50
Previous Close	49.64
Day's Range	48.62 - 51.00
52-Week Range	28.48 - 51.55
Beta	0.60
Analysts	Buy
Price Target	47.54 (-6.78%)
Earnings Date	Aug 25, 2026

About WuXi Biologics

WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People’s Republic of China, North America, Europe, Singapore, Japan, South Korea, Australia, and Brazil. It operates through two segments: Biologics and XDC. The company provides a suite of solutions for biologic discovery, from concept to IND, that seamlessly transits to CMC and downstream process development through its contract research, development, and ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 13,252
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2269

Financial Performance

In 2025, WuXi Biologics's revenue was 21.79 billion, an increase of 16.68% compared to the previous year's 18.68 billion. Earnings were 4.91 billion, an increase of 46.25%.

Financial numbers in CNY

Analyst Summary

According to 25 analysts, the average rating for 2269 stock is "Buy." The 12-month stock price target is $47.54, which is a decrease of -6.78% from the latest price.

Price Target

$47.54

(-6.78% downside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 21, 2026

Data Sources Report a data error